Pfizer files for U.S. authorization of promising COVID-19 antiviral pill
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Pfizer (PFE) Announces Agreement to Supply 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to US Govt
November 18, 2021 6:45 AM ESTPfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). If approved or authorized, PAXLOVID, which originated in Pfizers... More
Pfizer (PFE) Announces CFO Retirement
November 17, 2021 6:46 AM ESTPfizer Inc. (NYSE: PFE) today announced that Frank DAmelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year distinguished career with the Company. Pfizer has initiated an external search for a new Chief Financial Officer and DAmelio has agreed to stay on board through this process and serve in a consulting role through the transition. With DAmelios planned departure, and his significant contributions to Pfizers manufacturing capabilities, the Company has made the decision to name Mike McDermott, Executive... More
